Arena Pharmaceuticals Inc

Arena Pharmaceuticals — Investor Day (October 2018)

64 slides from Arena Pharmaceuticals's investor day presentation, Oct 4, 2018

  1. Slide 1: Arena R&D Day

    ARENA R&D DAY Nasdaq: ARNA October 4, 2018 Exhibit 99.1

  2. Slide 2: Forward-looking statements

    This presentation includes forward-looking statements that involve a number of risks and uncertainties, including statements about the Arena investment thesis, catalysts, value, our investigative stage drug candidates, including with respect to their potential (including to become first or best-in-c

  3. Slide 3: Presenters and Agenda

    Amit D. Munshi President & Chief Executive Officer Preston Klassen, MD, MHS Executive Vice President, R&D and Chief Medical Officer William J. Sandborn, MD UCSD Victor F. Tapson, MD, FCCP, FRCP Cedars-Sinai Presenters and Agenda AGENDA Introductions and corporate overview ~25 min Etrasimod ~30 min +

  4. Slide 4: Arena Management in Attendance

    Arena Management in Attendance John Adams, PhD Vice President, Translational Science Vince Aurentz Executive Vice President, Chief Business Officer Chris Cabell, MD, MHS, FACC Senior Vice President, Clinical Development Kevin Lind Executive Vice President, Chief Financial Officer Suzanne Zoumaras Ex

  5. Slide 5: Deep Pipeline with Therapeutic Focus

    Ralinepag Potent IP Receptor Agonist PAH - Time to Clinical Events Ph 3 Initiated PAH – Ex Capacity 6MWD Ph 3 PAH – Ex Capacity CPET Ph 3 PAH - Differentiation 1H:19 Initiation APD418 Calcium-Independent Myofilament Derepressor Decompensated heart failure (DHF) IND 2019 Deep Pipeline with Therapeuti

  6. Slide 6: Next Stage in Arena Evolution

    Next Stage in Arena Evolution Arena Resets and Builds… 3 Positive Ph 2 Readouts 250%+ Employee Growth Over 24 Mos ~70% of FTEs in R&D (100+ in R&D) 75% New Board 90% New Management 4+ Strategic Deals and Renegotiations ~70% Retail to 85% Institutional Holders

  7. Slide 7: Next Stage in Arena Evolution

    Next Stage in Arena Evolution 3 Positive Ph 2 Readouts 250%+ Employee Growth Over 24 Mos ~70% of FTEs in R&D (100+ in R&D) 75% New Board 90% New Management 4+ Strategic Deals and Renegotiations ~70% Retail to 85% Institutional Holders Arena Resets and Builds… 4 First- or Best-in-Class Compounds Up t

  8. Slide 8: Arena Opportunity

    Arena Opportunity Ralinepag Ph 3 PAH - potential $1-2B opportunity Etrasimod Ph 3 IBD (UC & CD) - potential $3-4B opportunity Etrasimod Ph 2 new indications (liver and derm) - potential $1.5-4B opportunity Olorinab Ph 2b IBS/IBD Pain - potential $1-3B opportunity Arena Pipeline Represents $7-13B Com

  9. Slide 9: Substantial Catalysts 2019-2022

    Substantial Catalysts 2019-2022 Etrasimod UC Open Label Data Read-Out Etrasimod UC Ph 3 Initiation Etrasimod CD Ph 2/3 Initiation Etrasimod AD Ph 2 Initiation Etrasimod CD Ph 3 Initiation Etrasimod UC Ph 3 Data Read-Out Etrasimod PBC Ph 2 Readout Etrasimod AD Ph 2 Data Read-Out Etrasimod AD Ph 3 Ini

  10. Slide 10: Etrasimod

    Etrasimod Oral, Next Generation, S1P Receptor Modulator with Optimized Activity Being Evaluated In Multiple Immune-Inflammatory Diseases

  11. Slide 11: Significant Opportunity to Improve IBD Standard of Care

    Significant Opportunity to Improve IBD Standard of Care Source: 1UC & CD Disease Landscape & Forecast Reports. DRG. 2018. 2The Facts About IBDs. Crohn’s & Colitis Foundation of America. 2014. 3European Population IBD Prevalence. European Crohn’s and Colitis Organization website viewed Sep 2016. 4Hir

  12. Slide 12: Etrasimod Emerging as Potential Market Leader

    Source: Arena data on file 100 GI Physicians Quantitative Conjoint Study Shows Etrasimod Emerging as Potential Market Leader Mod/Severe Patients Not Receiving Biologics Etrasimod vs. Ozanimod (Estimated Future Preference) Oral Market Increasing (Estimated Future Preference) S1P vs. JAK (Estimated Pr

  13. Slide 13: Etrasimod Demonstrates Competitive Efficacy in UC

    Source: Etrasimod: Post-hoc analysis. Δ=% difference from placebo estimated using Mantel-Haenszel method adjusted with current oral corticosteroid use and prior exposure to TNFα antagonists.. Sources: Ozanimod: Sandborn, et al. NEJM 2016; Xeljanz: Sandborn, et al. NEJM 2017; Entyvio: Feagan, et al.

  14. Slide 14: Etrasimod Remission at 12 Weeks

    Proportion of Patients with with Total Mayo Clinic Score ≤ 2 points and No Subscore > 1 point Total MCS = Mayo Clinic Score. Etrasimod: Post-hoc analysis. Δ=% difference from placebo estimated using Mantel-Haenszel method adjusted with current oral corticosteroid use and prior exposure to TNFα antag

  15. Slide 15: Etrasimod's Highly Selective Activity at S1P1,4,5

    S1P = Sphingosine 1-phosphate; UC = ulcerative colitis. *Data generated at Arena or under sponsored research by Arena Arena data on file. Spiegel & Milstien Nat Rev Immunol 2011;11:403-415. Jain & Bhatti Neurology 2012;78:672-689 Etrasimod’s Highly Selective Activity at S1P1,4,5 Reduces Inflammation

  16. Slide 16: Etrasimod Pharmacology and Barrier Function

    Better mucosal healing Healthier, intact intestinal epithelium reduces migration of microbiota, thus reducing inflammation Enhanced endothelial barrier function potentially reduces side effects, such as macular edema and PFT abnormalities Source: Spiegel S, et al. Nat Rev Immunol. 2011 Jun; 11(6): 4

  17. Slide 17: Advancing to Ph 3 in UC & Crohn's Disease

    Δ=% difference from placebo estimated using Mantel-Haenszel method adjusted with current oral corticosteroid use and prior exposure to TNFα antagonists. Arena data on file. Advancing to Ph 3 in UC & Crohn’s Disease Ulcerative Colitis (UC) Optimize study design Bigger effect size Expedited trial desi

  18. Slide 18: Ph 3 Program in UC Designed for Speed to Market

    Ph 3 Program in UC Designed for Speed to Market Study 1 Adults Biologics/JAK inhibitor: 50% naïve 50% exposed Etrasimod, 2 mg Placebo Week 12 Week 52 Primary Endpoints Study 1: Week 52 clinical remission (modified Mayo Clinic score) Study 2: Week 12 clinical remission (modified Mayo Clinic score) Po

  19. Slide 19: Ph 2/3 Program in Crohn's Disease

    Ph 3 Program in Crohn’s Disease Designed for Rapid POC & Speed to Market Maintenance Adults Prior Biologics: 50% naïve 50% exposed Week 12 Week 52 Primary Endpoints Remission (symptomatic improvement), and endoscopic remission (co-primary) Potential Secondary Endpoints Improvement in CDAI Induction

  20. Slide 20: Etrasimod May Have Applications in Broad Range of Diseases

    Etrasimod May Have Applications in Broad Range of Diseases Catenion Analysis & Current product development for S1P receptor modulators GI Ulcerative Colitis Crohn’s Disease Liver Primary Biliary Cholangitis Autoimmune Hepatitis Primary Sclerosing Cholangitis Skin Atopic Dermatitis Psoriasis Sclerode

  21. Slide 21: Etrasimod Aiming to Address Unmet Need in PBC

    Autoimmune disease resulting in destruction of bile ducts, progressive fibrosis & hepatic failure Primary Biliary Cholangitis (PBC) Cholestasis, Ductopenia & Fibrosis Intrahepatic Bile Duct Etrasimod Cirrhosis & End-stage Disease Injury by T Cells Autoimmune Trigger Source: 1Primary Biliary Cholangi

  22. Slide 22: Etrasimod and Inflammatory Dermatological Diseases

    Etrasimod Has Potential to Impact Broad Range of Inflammatory Dermatological Diseases DC TH1 TH17 TH2 TH22 Epidermis Lymph Node T T Dermis T cell driven inflammation in multiple immune-mediated skin diseases Etrasimod may improve skin disease by inhibiting dendritic cell & T cell trafficking Etrasim

  23. Slide 23: S1P1 & S1P4 Modulate Dendritic Cell Migration in Skin

    1- Schulze et al. FASEB 2011;25. S1P1 & S1P4 Modulate Dendritic Cell Migration and Cytokine Expression in Skin S1P4-/- mice have exacerbated inflammation in contact hypersenstivity1 DC WT control S1p4-/- control WT FITC S1p4-/- FITC CD8+ CD44+ CD62L- 40 20 0 * 500 250 0 Absolute cell numbers [x103]

  24. Slide 24: Etrasimod Preclinical Data Support Dermatologic Indications

    Arena data on file. * p < 0.05 compared to vehicle. ** p < 0.0001 compared to vehicle. Mpk = milligram per kilogram Etrasimod Preclinical Data Further Support Dermatologic Indications as Potential Therapeutic Area ** ** ** ** Vehicle Etrasimod 3 mpk * * * Etrasimod reduced collagen deposition and de

  25. Slide 25: Etrasimod's Clinical Activity in Skin Disorders

    Etrasimod’s Clinical Activity in Patients Supports Ongoing Investigation in Skin Disorders Evaluated data on 7 patients with dermatological manifestations 5/6 etrasimod-treated patients showed improvement in DLQI scale - - in either pyoderma gangrenosum (PG) or extraintestinal manifestations (EIM) o

  26. Slide 26: Etrasimod Early Result in Pyoderma Gangrenosum

    Etrasimod Early Clinical Result in Pyoderma Gangrenosum Baseline Image Initial Measurement (7/5/17) Current Image Date of Assessment (9/27/17) Initial Area (CmSq) Current Area (CmSq) Percent Area Change Length 4.668 1.520 -67.44% 2.18cm

  27. Slide 27: Focus on Exploring Atopic Dermatitis

    Focus on Exploring Atopic Dermatitis Source: 1Atopic Dermatitis/Atopic Eczema. Disease Landscape & Forecast. DRG. August 2018. 2Silverberg, JI. Dermatol Clin. 2017 Jul;35(3):283-289. 3Barbarot S, et al. Allergy. 2018 Jun;73(6):1284-1293. 4Atopic Dermatitis: Survey of 192 Patients. National Eczema As

  28. Slide 28: Etrasimod Program Timeline 2018-2022

    Etrasimod Program Timeline 2018-2022 Roadmap 2018 2019 2020 2021 2022 2023 1H 2H 1H 2H 1H 2H 1H 2H 1H 2H Ulcerative Colitis Crohn’s Disease Liver Disease CD: Ph 3 Maintenance CD: Open Label Long-term Extension (OLE) PBC Ph 2 Data Derm AD Ph 2 Interim Analysis Planned Data Legend: Open-label Pending

  29. Slide 29: Etrasimod Progressing Rapidly with Best-in-Class Profile

    Well characterized, developed in-house Higher selectivity drives efficacy with no off-target activity Improved PD – rapid on-rate + rapid off-rate with true 36 hour half-life UC data supportive of category leading efficacy with good safety / tolerability Moving to Ph 3 in UC, Crohn’s to validate saf

  30. Slide 30: Ralinepag

    Ralinepag Next-Generation, Oral, Selective, Once-Daily Prostacyclin Receptor (IP) Agonist for Pulmonary Arterial Hypertension

  31. Slide 31: Changing the Game - Benefits of IV Prostacyclin in Oral Therapy

    Source: 1Pulmonary Hypertension. Disease Landscape & Forecast. DRG. November 2016. 2Pulmonary Hypertension. DRG. September 2014. 3Coghlan JG, et al. Am J Cardiovasc Drugs. 2018 Feb;18(1):37-47. 4Benza RL, et al. Chest. 2012 Aug;142(2):448-456. 5Burger CD, et al. J Manag Care Spec Pharm. 2018 Mar;24(

  32. Slide 32: Market Research Supports Ralinepag's Leading Position

    ” ” ” ” Source: 1Burger CD, et al. J Manag Care Spec Pharm. 2018 Mar;24(3):291-302. 2Arena market research, Sept. 2018 Market Research Supports Broad Opportunity and Potential for Ralinepag’s Leading Position Patients on Prostacyclin1 (2015) Oral Prostacyclin Projected Dynamics2 Oral PC Class Growin

  33. Slide 33: Unremitting Receptor Engagement Improves Survival in PAH

    Cumulative Survival Epoprostenol Historical Control Month Long Term Source: 1 Barst RJ, et al. N Engl J Med. 1996 Feb 1;334(5):296-301. 2 Sitbon O, et al. J Am Coll Cardiol . 2002 Aug 21;40(4):780-8. Decision Resources 2016. Unremitting Receptor Engagement and Potency Improves Survival In PAH Surviv

  34. Slide 34: Ralinepag Impressive PVR Improvement

    *PVR, change in least squares mean from placebo; **Flolan: Barst et al NEJM 1996 Feb 1;334(5): 296-301 Ralinepag Impressive PVR Improvement Ralinepag (n=40) Placebo (n=40) Placebo (n=21) -20.1% -21% Flolan® (n=41) 9% -30%** 9.6% -29.8%* Note: No direct head-to-head data available - Caution advised w

  35. Slide 35: Clear Ph 3 Objectives for Best-in-Disease Treatment

    Clear Ph 3 Objectives for a Potential Best-in-Disease Treatment Objective Time-to-Clinical Event Exercise Capacity Time to Market ü ü Breadth of Label ü ü ü Broad Physician Experience ü ü ü Supports use in prevalent patients Supports early use in newly diagnosed patients

  36. Slide 36: Trial Assumptions for the ADVANCE Program

    Source: Protocol amendment 1 for: APD811-301, APD811-302, and APD811-304. Trial Assumptions for the ADVANCE Program Design Parameter 301 302 304 Endpoint TtCE Peak V02 (CPET) 6MWD Sample 700 135 290 p <0.01 <0.05 <0.05 Power 90% 90% 90% Hazard Ratio / Treatment Effect HR = 0.6 TE = 1.8 ml O2/Kg/min

  37. Slide 37: Ralinepag Program Designed to Differentiate vs. Selexipag

    Ralinepag Program Designed to Differentiate vs. Selexipag Abbreviations: PK, Pharmacokinetic; PD, Pharmacodynamic; XR, Extended Release; PVR, Pulmonary Vascular Resistance; CPET, Cardiopulmonary Exercise Test; MRI, Magnetic Resonance Imaging; 6MWD, 6 minute walk distance; PAH; Pulmonary Arterial Hyp

  38. Slide 38: Ralinepag Differentiation Study

    Hemodynamic data on patients as they switch from selexipag to ralinepag Hypotheses - Compared to selexipag, ralinepag will have improved PVR at both peak and trough Ralinepag Differentiation Study Baseline Measurement Minimum 30 days treatment PVR Subjects enter ralinepag OLE Ralinepag levels for PK

  39. Slide 39: Ralinepag Open-Label Extension Study Overview

    Ralinepag Open-Label Extension (OLE) Study Overview Abbreviations: OLE, Open Label Extension; RHC, Right Heart Catherization; BID, Twice Daily; mg; milligram; FC, Functional Class; 6MWT, 6-Minute Walk Test ~28 Day Screening Period 22-week Treatment Period 9-Week Dose Titration Period 13-Week Treatme

  40. Slide 40: Ralinepag OLE Baseline Demographics

    Ralinepag OLE Baseline Demographics Safety Population – Original (003) Baseline Ralinepag/Ralinepag (N=30) Placebo/Ralinepag (N=15) Age (years) 46 (13) 56 (11) Female/Male (%) 80/20 100/0 PAH Duration (median [range]) 2.5 (0.3-27) 1.8 (0.3-14) PAH Concomitant Medication PDE5i mono 10 (33%) 4 (27%) E

  41. Slide 41: Ralinepag Demonstrated Long-Term Hemodynamic Improvement

    Ralinepag Demonstrated Long-Term Hemodynamic Improvement D PVR D %PVR -250 -200 -150 -100 -50 0 D P V R ( d y n · s · c m - 5 ) Ralinepag/Ralinepag (N=18) Placebo/Ralinepag (N=11) median 003 Start 007 Start OLE RHC -50 -40 -30 -20 -10 0 D P V R ( % ) Ralinepag/Ralinepag (N=18) Placebo/Ralinepag (N=1

  42. Slide 42: Ralinepag Sustained Improvement in Exercise Capacity

    Ralinepag Demonstrated Sustained Improvement in Exercise Capacity Improvement from Start of Ralinepag Treatment *=p<0.05, **=p<0.01, ***=p<0.001 vs. Original (003) Baseline for Ralinepag/Ralinepag and 007 Baseline for Placebo/Ralinepag At last observation (OLE LOCF): 47% (7/15) PBO/Ralinepag subject

  43. Slide 43: Ralinepag OLE Safety and Tolerability

    Ralinepag OLE Safety and Tolerability Among patients originally randomized to ralinepag in Ph 2 trial, continuation in OLE was associated with a reduced incidence of tolerability events (i.e., headache, jaw pain, etc.) Overall adverse event profile is consistent with the Ph 2 trial and with the unde

  44. Slide 44: Ralinepag Program Timeline 2018-2022

    Ralinepag Program Timeline 2018-2022 Roadmap 2018 2019 2020 2021 2022 1H 2H 1H 2H 1H 2H 1H 2H 1H 2H Open Label Extension (APD811-007) and (APD811-303) Ph 3 Program ADVANCE OUTCOMES (APD811-301) ADVANCE CAPACITY (APD811-302) Differentiation Program ADVANCE ENDURANCE (APD811-304) Topline LSLV Topline

  45. Slide 45: Ralinepag is a Game-Changing Therapy for PAH Patients

    Unremitting 24-hour receptor coverage with 6.5-10x potency of selexipag Best-in-Class 20.1% PVR over dual background therapy Ph 3 initiated with most robust program ever developed Additional non-registrational studies to support superiority over selexipag Ralinepag Ph 3 PAH - potential $1-2B opportu

  46. Slide 46: Olorinab

    Highly–Selective, Full Cannabinoid 2 Receptor (CB2) Agonist for Gastrointestinal Pain Olorinab

  47. Slide 47: Olorinab May Address Clear Unmet Need in GI Pain

    Olorinab May Address Clear Unmet Need in GI Pain Sources: 1 DRG: IBS Report (2015), 2 IFFGD & UNC: Online Study, n=1,966 (2007), 3 Allergan: Global Impact Report (2018), 4 ZS Analysis (U.S. Census/Datamonitor), 5 CDC: MMWR Prevalence of IBD, n=33,672 (2016), 6 Arena market research, 7 Waljee, Eur J

  48. Slide 48: Olorinab Potential Best-in-Class Profile

    Source: 1 DRG: IBS Report (2015), 2The Facts About IBDs. Crohn’s & Colitis Foundation of America. 2014. 3Drossman DA, et al. J Clin Gastroenterol. 2009 Jul; 43(6): 541–550. 4Adelphi 2017. 5Hacker B, et al. P216. Presented at: Crohn’s & Colitis Congress; Jan. 19-20, 2018; Las Vegas, NV. 6Camilleri M,

  49. Slide 49: CB2 Receptors in the GI Tract

    CB2 receptors represent a pathophysiological mechanism in GI tract to regulate abnormal motility, modulate intestinal inflammation & limit visceral sensitivity/pain CB2 Receptor Expression in the GI Tract CB2 receptors located in target tissue, neurons & local immune cells in GI tract CB2 receptor a

  50. Slide 50: Olorinab Strong Pre-Clinical Efficacy in IBD Model

    Castro J, et al. Poster presented at the IASP World Congress on Pain; September 12-16, 2018. ***p<0.001, ****p<0.0001 (comparison to healthy + vehicle); ### p<0.001, #### P<0.0001 (comparison to TNBS + vehicle) Olorinab Demonstrates Strong Pre-Clinical Efficacy in IBD Model * ** *** Olorinab (nM) *p

  51. Slide 51: Shared Mechanisms in IBS and IBD Pain

    1. Barbara et al., (2014) Curr Opin Gastroenterol 30:352-358; 2. Cremon et al., (2017) Alimentary Pharmacology and Therapeutics 45:909-922; 3. Dr. Lin Chang, unpublished data; 4. Spiller and Major (2016), Nat Rev Gastroenterol Hepatol 13(10):613-21; 5. Vivinus-Nebot et al., (2013) Gut 63:744-752 Sha

  52. Slide 52: Olorinab Strong Pre-Clinical Efficacy in IBS Model

    Arena data, study being performed by Stuart Brierley's group; Hughes et al., (2009) Gut 58,1333-1341. CVH, Chronic Visceral Hypersensitivity; olorinab given BID (days 24-28) Olorinab Evidences Strong Pre-Clinical Efficacy in IBS Model Vehicle (N=14) Vehicle (N=14) Healthy IBD-like IBS-like Colitis i

  53. Slide 53: Olorinab Ph 2a Study in Crohn's Disease

    Exploratory Objectives Abdominal Pain Score (APS) Patient reported outcome (PRO) C-Reactive Protein (CRP) Average Abdominal Pain Score (AAPS) Patient Health Questionnaire (PHQ)-9 Fecal calprotectin and other biomarkers Weekly or end-of-treatment responders Crohn’s Disease Activity Index (CDAI) PK pr

  54. Slide 54: Strong Signal in Average Abdominal Pain Score

    Strong Signal in Average Abdominal Pain Score (AAPS) and Responder Analysis Source: Table 13 AAPS Improvement -4.6 *=p<0.05; **=p<0.01 85% of patients improved at week 4 100% of patients improved at week 8 (Evaluable Population with ≥30% change from baseline in AAPS)

  55. Slide 55: Successful Ph 2a Study Results Inform Development Path

    Successful Ph 2a Study Results Inform Development Path Olorinab trial results demonstrate meaningful efficacy in patients with Crohn’s disease experiencing abdominal pain Reductions in abdominal pain seen within first wk of treatment Statistically significant improvements in pain over 8 wks of treat

  56. Slide 56: APD418

    A First-in-Class Calcium-independent Myofilament Derepressor (CMD) for Decompensated Heart Failure (DHF) APD418

  57. Slide 57: APD418 is First-in-Class for DHF with Novel MOA

    Source: 1Heart Failure. Disease Landscape & Forecast. DRG. June 2018. 2Dharmarajan K, et al. BMJ. 2015 Feb 5;350:h411. 3Nielsen DV, et al. Anesthesiology. 2014 May;120(5):1098-108. APD418 is First-in-Class for DHF with Novel MOA 70% readmitted within 1 year2 20% increased mortality with each rehospi

  58. Slide 58: Decompensated Heart Failure Patients Deserve Better Options

    Mebazaa A, et al. Intensive Care med. 2011 Feb;37(2):290-301. Nielsen DV, et al. Anesthesiology. 2014 May;120(5):1098-108. Intensive Care Med (2011) 37:290-301. DOI 10.1007/s00134-010-2073-4 Decompensated Heart Failure Patients Deserve Better and Safer Therapeutic Options Known Issues with Inotropes

  59. Slide 59: Cardiac Decompensation Leads to Contractility Repression

    Normal Cardiac Myocyte Cardiac Decompensation Leads to Contractility Repression Normal Contractility b3 b1 / b2 Image adapted from: Kulandavelu S, et al. J Am Coll Cardiol. 2012;59(22):1988-1990. Minimal Repression Decompensated Cardiac Myocyte Decreased Contractility b3 b1 / b2 Strong Repression Ag

  60. Slide 60: Targeted Therapy for Cardiac Myocyte Dysfunction

    Calcium-independent Myofilament Derepressor via b3 adrenergic receptor antagonism Improves cardiac contractility with minimal effect on intracellular calcium Avoids inotrope-associated AEs Unique myocyte-specific target to regulate contractility Decompensated Cardiac Myocyte Increased Contractility

  61. Slide 61: Improved Cardiac Function Without Hemodynamic Liability in Animals

    Increased Cardiac Performance Improved Cardiac Function Without Hemodynamic Liability in Animals Supports Advancement Into Clinic Canine model. Arena data on file. Improved Cardiac Safety Cardiac Output (L/min) LV Ejection Fraction (%) Heart Rate (beats/min) Mean Aortic Pressure (mmHg)

  62. Slide 62: APD418 First-in-Class Novel Therapy for DHF

    Decompensated heart failure is an area of high unmet medical need with significant morbidity and mortality Current standard of care to improve contractility results in increased long-term mortality (inotropes) APD418 targets a novel mechanism that improves contractility without adverse hemodynamic c

  63. Slide 63: Summary

    Summary 4 First- or Best-in-Class Compounds Up to 4 NDAs By 2022/2023 7 Phase 3 Trials 4 Phase 2 Trials Preclinical / New Compounds Multiple Catalysts 2019/2020 Arena Pipeline Represents $7-13B Commercial Opportunity

  64. Slide 64: Thank you

    Thank you Nasdaq: ARNA

Arena Pharmaceuticals — Investor Day (October 2018) on 6ix